Loading today’s stories

Today

AI-assisted reporting, grounded in a per-article claim ledger. Perspective Coverage and Reality Strip separate source viewpoints from evidence, adoption, hype, incentives, and confidence.

Today

Front Page
Today’s Briefing
Newsletters
Trending
For You
Discover
My Stack
Saved
Off Radar
Search

Sections

Security
Build
Invest
Product
Leadership
Science

Company

About
Mission
How this is made
Evidence Index
The desks
The sources we read
Corrections
Press and brand
The daily edition

Trending now

Teen online safety
AI Copyright Litigation
Strategic Corporate Investment
Retail Investor Protection
Crypto Fraud Enforcement
Illicit Crypto Flow Measurement
Conflicts of Interest in Policy
Metric Integrity
LLM Evaluation
Post-Quantum Cryptography

How this is made

Today For You My Stack Off Radar Search

Ascidian Therapeutics — company — Clarity Today

company

Ascidian Therapeutics

Boston-based RNA exon editing company that partnered with Lilly in June on inherited kidney disease, a deal worth potentially more than $1.9 billion to Ascidian.

Known aliases

Ascidian

Relationships

No evidence-backed relationships are recorded.

Current clusters

science1 distinct publisher

Massachusetts biotech: growth-stage money is back, seed money and NIH awards are not

MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.

Publishers:genengnews.com

Reality

Evidence61
Adoption58
Hype gap+12
Incentives74

Confidence63